ERS Genomics licenses gene editing tech to G+FLAS
ERS Genomics has signed a nonexclusive licensing deal granting G+FLAS Life Sciences access to its CRISPR/Cas9 patent portfolio. Read More
Luminary licenses TcBuster CAR T tech from Bio-Techne
Luminary Therapeutics has signed a license agreement with Bio-Techne for the use of its TcBuster chimeric antigen receptor (CAR) T technology for the manufacturing of gene-modified cell therapies. Read More
Sirion Biotech, Sanofi to improve AAV capsids
Sirion Biotech has signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors for the development of effective gene therapies. Read More
GemPharmatech branches out with preclinical research sites in U.S.
China's GemPharmatech, a provider of laboratory animals, has launched new research sites in the U.S. that will house 6,000 research models. Read More
Thermo Fisher acquires cell-sorting technology from Propel Labs
Thermo Fisher Scientific acquired cell-sorting technology assets from Propel Labs, a wholly owned subsidiary of SIDIS. Under the terms of the agreement, the recently introduced Bigfoot Spectral Cell Sorter and approximately 40 employees will become part of Thermo Fisher's Biosciences business. Propel Labs will continue to operate as a separate entity, according to a press release. Read More
AI uncovers the genome's hidden regulatory code
A neural network trained on high-resolution maps of protein-DNA interactions can uncover how these sequences are organized to regulate genes, revealing a hidden regulatory code. Findings from use of the artificial intelligence (AI) model were published in Nature Genetics on February 18. Read More
Precision BioSciences demonstrates long-term efficacy of genome editing
Precision BioSciences has demonstrated the use of its Arcus genome editing platform to achieve long-term stable reduction of low-density lipoprotein cholesterol levels in nonhuman primates following in vivo gene editing of the PCSK9 gene. Read More
Selecta, AskBio start gene therapy ImmTor trial
Selecta Biosciences and Asklepios BioPharmaceutical (AskBio) have initiated a phase I clinical trial to evaluate the safety and preliminary efficacy of ImmTor in gene therapy. Read More
Charles River to pay $875M to buy Cognate BioServices
Charles River Laboratories has signed a deal to pay about $875 million in cash to acquire cell and gene manufacturer Cognate BioServices. Read More
Proteomics helps researchers pick the best anti-SARS-CoV-2 nanobodies
A new high-throughput proteomics-based strategy to identify tiny antibody fragments -- called nanobodies -- may provide an efficient and effective method for developing therapeutics against the deadly SARS-CoV-2 virus -- including variants. The findings were published in Cell Systems on February 15. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter